Northwest Biotherapeutics, Inc  

(Public, NASDAQ:NWBO)   Watch this stock  
8.27
0.00 (0.00%)
Real-time:   12:11PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.11 - 8.32
52 week 3.79 - 9.45
Open 8.30
Vol / Avg. 95,140.00/473,140.00
Mkt cap 635.87M
P/E     -
Div/yield     -
EPS -2.11
Shares 76.89M
Beta 2.86
Inst. own 25%
May 7, 2015
Northwest Biotherapeutics Inc at (NAIC), PR Newswire and BetterInvesting Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -23934.54% -9328.34%
Operating margin -11768.56% -6925.31%
EBITD margin - -6955.43%
Return on average assets -345.36% -351.27%
Return on average equity - -
Employees 12 -
CDP Score - -

Address

Suite 800, 4800 Montgomery Lane
BETHESDA, MD 20814
United States - Map
+1-240-4979024 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Northwest Biotherapeutics, Inc., is a development stage biotechnology company focused on developing immunotherapy products to treat cancers, without toxicities of the kind associated with chemotherapies, and, through a proprietary batch manufacturing process, on a cost-effective affordable basis initially in both the United States and Europe. The Company is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than existing treatments, and without the side effects of chemotherapy drugs. The Company has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The DCVax technology is expected to be applicable to most cancers, and is embodied in several distinct product lines: DCVax-L, DCVax-Direct and DCVax-Prostate.

Officers and directors

Linda F. Powers Chairperson of the Board, President, Chief Executive Officer
Age: 58
Bio & Compensation  - Reuters
Leslie J. Goldman Senior Vice President - Business Development
Age: 69
Bio & Compensation  - Reuters
Anthony E. Maida Ph.D. Senior Vice President - Clinical Research
Age: 61
Bio & Compensation  - Reuters
Marnix L. Bosch Ph.D Chief Technical Officer
Age: 54
Bio & Compensation  - Reuters
Alton L. Boynton Ph.D. Chief Scientific Officer, Director
Age: 70
Bio & Compensation  - Reuters
Robert A. Farmer Independent Director
Age: 74
Bio & Compensation  - Reuters
Jerry J. Jasinowski Independent Director
Age: 71
Bio & Compensation  - Reuters
Navid Malik Independent Director
Age: 45
Bio & Compensation  - Reuters